Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

As of April 30, 2025, there are 82 publicly listed companies in China engaged in the in vitro diagnostics (IVD) industry. Among them, 61 companies focus primarily on IVD, while 21 have IVD as part of their broader business portfolios.

Multiple diagnostic firms released preliminary earnings results for the fourth quarter and full year of 2021 on Monday, including CareDx, Castle Biosciences, Lucira Health, OpGen, Adaptive Biotechnologies, and Sema4.

Merck, a leading science and technology company, has signed a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately USD 780 million in cash.

Quidel is set to beat analyst expectations in the fourth quarter on the back of rising demand for COVID-19 tests that brought revenues up to around $635 million.

Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 25, 2021.

To make fusion energy a viable resource for the world’s energy grid, researchers need to understand the turbulent motion of plasmas: a mix of ions and electrons swirling around in reactor vessels.

Ortho Clinical Diagnostics announced preliminary financial results for the fourth quarter after the close of the market on Thursday, saying it expects total revenues of between $520 million and $522 million, up approximately 1 percent year over year from $517 million.

Thermo Fisher Scientific, the world leader in serving science, and PeproTech, a leading developer and manufacturer of recombinant proteins, today announced that Thermo Fisher completed its acquisition of PeproTech on December 30, 2021 for a total cash purchase price of approximately $1.85 billion.

On January 7, Hotgen Biotech released a performance forecast. The company expects the net profit attributable to the shareholders of the listed company from January to December 2021 to be CNY 2 billion to CNY 2.35 billion, with a year-on-year change of 1684.65% to 1996.97%.

Illumina said on Wednesday that it has entered into a codevelopment agreement with SomaLogic to create multiplexed, high-throughput proteomics assays with next-generation sequencing-based readout.

When a patient receives a kidney transplant, doctors carefully monitor them for signs of rejection in several ways, including biopsy. However, this procedure is invasive and can only detect issues at a late stage.